Meeting
2024 ASCO Genitourinary Cancers Symposium
Adverse effects and discontinuation of pembrolizumab in BCG refractory non-muscle invasive bladder cancer.
Authors
Borivoj Golijanin
The Minimally Invasive Urology Institute, Division of Urology, The Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI
Borivoj Golijanin , Kamil Malshy , Vikas Bhatt , Galina Lagos , Ali Amin , Andre Luiz De Souza , Liang Cheng , Anthony E. Mega , Dragan Golijanin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 588)
DOI
10.1200/JCO.2024.42.4_suppl.588
Abstract #
588
Poster Bd #
F15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.
First Author: Girish S. Kulkarni
Poster
2016 ASCO Annual Meeting
KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).
First Author: Ashish M. Kamat
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore
Poster
2023 ASCO Annual Meeting
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.
First Author: Hizra Farrukh